Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer

Eya Wolfson(Tel Aviv University), Ronit Pinkas‐Kramarski(Tel Aviv University)

Oncotarget

August 17, 2016

10.18632/oncotarget.11323

Cited by 38

Related Papers

Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer

|Cell Death and Disease|2018|43

Nucleolin inhibitor GroA triggers reduction in epidermal growth factor receptor activation: Pharmacological implication for glial scarring after spinal cord injury

|Journal of Neurochemistry|2016|10

Continuous treatment with FTS confers resistance to apoptosis and affects autophagy

|PLoS ONE|2017|4